Finerenone - Generic Drug Details

What are the generic drug sources for finerenone and what is the scope of patent protection?

Finerenone is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Finerenone has ninety-seven patent family members in forty-nine countries.

One supplier is listed for this compound.

Summary for finerenone

International Patents:	97
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	55
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for finerenone
What excipients (inactive ingredients) are in finerenone?	finerenone excipients list
DailyMed Link:	finerenone at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for finerenone

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for finerenone

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mansoura University	PHASE4
College of Physicians and Surgeons Pakistan	NA
Sarfez Pharmaceuticals, Inc.	PHASE3

See all finerenone clinical trials

Pharmacology for finerenone

Drug Class	Nonsteroidal Mineralocorticoid-Receptor Antagonist
Mechanism of Action	Mineralocorticoid Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for finerenone

C03DA	Aldosterone antagonists
C03D	ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS
C03	DIURETICS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for FINERENONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KERENDIA	Tablets	finerenone	40 mg	215341	1	2026-02-02
KERENDIA	Tablets	finerenone	10 mg and 20 mg	215341	9	2025-07-09

US Patents and Regulatory Information for finerenone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-003	Jul 11, 2025		RX	Yes	No				Y
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-002	Jul 9, 2021		RX	Yes	Yes			Y	Y
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-002	Jul 9, 2021		RX	Yes	Yes
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-002	Jul 9, 2021		RX	Yes	Yes				Y
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-002	Jul 9, 2021		RX	Yes	Yes
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-001	Jul 9, 2021		RX	Yes	No

EU/EMA Drug Approvals for finerenone

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bayer AG	Kerendia	finerenone	EMEA/H/C/005200Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.	Authorised	no	no	no	2022-02-16

International Patents for finerenone

Country	Patent Number	Title	Estimated Expiration
Japan	6824247
Japan	5752754
Peru	20090724
Hungary	E044574
Spain	2739904
Uruguay	38952	AMIDAS DE 4-ARIL-1,4-DIHIDRO-1,6-NAFTIRIDINA SUSTITUIDAS Y COMPOSICIONES FARMACÉU-TICAS QUE LAS CONTIENEN

Supplementary Protection Certificates for finerenone

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2132206	2290018-7	Sweden		PRODUCT NAME: FINERENONE AND ITS SALTS, SOLVATES AND SOLVATES OF THE SALT THEREOF; REG. NO/DATE: EU/1/21/1616 20220217
2132206	15/2022	Austria		PRODUCT NAME: FINERENON UND SALZE, SOLVATE UND SOLVATE DER SALZE DAVON; REGISTRATION NO/DATE: EU/1/21/1616 (MITTEILUNG) 20220217
2132206	2022C/538	Belgium		PRODUCT NAME: FINERENON EN ZIJN ZOUTEN, SOLVATEN EN SOLVATEN VAN DE ZOUTEN DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1616 20220217
2132206	CA 2022 00025	Denmark		PRODUCT NAME: FINERENONE OG DETS SALTE, SOLVATER OG SOLVATER AF SALTENE DERAF; REG. NO/DATE: EU/1/21/1616 20220217
2132206	SPC/GB22/031	United Kingdom		PRODUCT NAME: FINERENONE OR ITS SALT, SOLVATE OR SOLVATE OF A SALT THEREOF; REGISTERED: CH 68130 20211126; UK EU/1/21/1616(FOR NI) 20220217
2132206	301192	Netherlands		PRODUCT NAME: FINERENON EN ZIJN ZOUTEN, SOLVATEN EN SOLVATEN VAN DE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/21/1616 20220217

Market Dynamics and Financial Trajectory for Finerenone

Last updated: March 4, 2026

What Is Finerenone?

Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) developed primarily for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM). It is marketed under the brand name Kerendia by Bayer.

Current Market Status

• Approval: The U.S. Food and Drug Administration (FDA) approved Finerenone (Kerendia) in July 2021 for reducing the risk of sustained eGFR decline, end-stage renal disease (ESRD), cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with CKD associated with T2DM.
• Market Penetration: As of 2023, Finerenone holds a niche position with limited market penetration due to competition from existing MRAs like spironolactone and eplerenone, which are off-label used in similar indications.

Market Drivers

• Enhanced Safety Profile: Finerenone's decreased hyperkalemia risk compared to steroidal MRAs increases its appeal for CKD and T2DM patients.
• Growing CKD and T2DM Population: The global rise in CKD and T2DM prevalence drives demand. The International Diabetes Federation estimates 537 million adults with diabetes in 2021, expected to grow to 700 million by 2045 (IDF, 2021).
• Guideline Integration: The 2021 American Diabetes Association guidelines endorse Finerenone for CKD with T2DM, influencing prescribing behavior.
• Clinical Trials: Ongoing studies exploring combination therapies and expanded indications may widen market scope.

Competitive Landscape

Drug	Type	Approval Year	Indications	Market Share (2023)
Finerenone (Kerendia)	Non-steroidal MRA	2021	CKD with T2DM	10%
Spironolactone	Steroidal MRA	Off-label	Heart failure, hypertension	50% (off-label)
Eplerenone	Steroidal MRA	2002	Heart failure, post-myocardial infarction	40%

Market Challenges

• Limited Indications: Currently approved only for CKD with T2DM.
• Pricing and Reimbursement: Novel drugs face reimbursement hurdles; premium pricing may limit uptake.
• Generics and Off-Label Use: Widespread use of cheaper off-label options reduces market share potential.
• Competitive Pipeline: Several pipeline candidates for CKD and cardiovascular indications threaten long-term growth.

Financial Trajectory and Forecasts

Revenue Estimates

• 2023: Estimated global sales below $200 million, driven by initial uptake in regulatory-approved markets.
• 2024-2025: Projected compound annual growth rate (CAGR) of 20-25%, reaching approximately $400-500 million by 2025, assuming increased adoption and expanded indications.

Key Growth Factors

• Expansion into Europe and Asia-Pacific markets.
• Inclusion in future guideline updates and clinical practice.
• Successful completion of new clinical trials demonstrating broader efficacy.

Risks

• Rapid generic entry of steroidal MRAs could undermine Finerenone's adoption.
• Regulatory delays or unfavorable trial results could constrain growth.
• Competitive drugs with superior safety profiles or broader indications could limit market share.

Strategic Outlook

Bayer targets global expansion and clinical trial progress to solidify Finerenone's position. The drug's growth hinges on its ability to differentiate from off-label uses of existing MRAs and to demonstrate value through ongoing research.

Key Takeaways

• Finerenone launched in 2021; its market remains niche but expanding.
• Growth depends on broader guideline acceptance and international approval.
• Competition from steroids remains a challenge; safety advantages position Finerenone favorably.
• Financial trajectory indicates accelerating revenues, with significant upside contingent on clinical and regulatory developments.
• Market expansion into new indications and regions represents a strategic priority.

FAQs

1. What are the main advantages of Finerenone over traditional MRAs? Finerenone offers a lower risk of hyperkalemia and better selectivity, making it safer for patients with CKD and T2DM.

2. Which markets are most critical for Finerenone's growth? The U.S., Europe, and Asia-Pacific are the key regions, driven by rising CKD and T2DM prevalence.

3. How does off-label use affect Finerenone’s market potential? Widespread use of cheaper steroids for similar indications limits market share, but Finerenone’s safety profile can increase adoption if guidelines endorse its use.

4. What are the upcoming clinical trials for Finerenone? Trials exploring cardiovascular benefits, combination therapies, and expanded CKD populations are ongoing to support broader indications.

5. How can Bayer enhance Finerenone’s market penetration? Through additional trials, guideline updates, price strategies, and geographical expansion.

References

1. International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th edition. https://www.diabetesatlas.org
2. U.S. Food and Drug Administration. (2021). FDA Approves Finerenone for CKD in Adults with T2DM. https://www.fda.gov
3. Bayer. (2023). Kerendia (Finerenone) Prescribing Information. https://www.bayer.com